有前景的非噻吩并吡啶类抗血小板药物的临床概述

Clinical overview of promising nonthienopyridine antiplatelet agents.

作者信息

Angiolillo Dominick J, Guzman Luis A

机构信息

Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL FL32209, USA.

出版信息

Am Heart J. 2008 Aug;156(2 Suppl):S23-8. doi: 10.1016/j.ahj.2008.06.006.

DOI:10.1016/j.ahj.2008.06.006

PMID:18657683

Abstract

Three novel nonthienopyridine antiplatelet agents--cangrelor, ticagrelor (AZD6140), and SCH 530348--are in advanced clinical testing in patients with coronary artery disease. Cangrelor and ticagrelor are direct and reversible inhibitors of the platelet adenosine 5'-diphosphate P2Y12 receptor, whereas SCH 530348 is a thrombin receptor antagonist. Clinical data available to date for each of these compounds suggest that they have safety and efficacy profiles that will be advantageous to patients with acute coronary syndromes or undergoing percutaneous intervention. We review the clinical features of these new platelet inhibition therapies.

摘要

三种新型非噻吩并吡啶类抗血小板药物——坎格雷洛、替卡格雷洛（AZD6140）和SCH 530348——正在冠心病患者中进行晚期临床试验。坎格雷洛和替卡格雷洛是血小板腺苷5'-二磷酸P2Y12受体的直接可逆抑制剂，而SCH 530348是一种凝血酶受体拮抗剂。目前可获得的关于这些化合物的临床数据表明，它们具有的安全性和有效性特征将对急性冠脉综合征患者或接受经皮介入治疗的患者有利。我们综述了这些新型血小板抑制疗法的临床特点。